Belantamab mafodotin
207503-JPN
Phase 3 small_molecule active
Quick answer
Belantamab mafodotin for Multiple Myeloma is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Multiple Myeloma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active